Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study

The Lancet. Gastroenterology & Hepatology
Brian G CzitoMichael Michael

Abstract

Further optimisation of present standard chemoradiation is needed in patients with locally advanced rectal cancer. Veliparib, an oral poly(ADP-ribose) polymerase inhibitor, has been shown to enhance the antitumour activity of chemotherapy and radiotherapy in preclinical models. We aimed to establish the maximum tolerated dose and establish the recommended phase 2 dose of veliparib combined with neoadjuvant capecitabine and radiotherapy. This phase 1b, open-label, multicentre, dose-escalation study was done at six hospitals (one in Australia and five in the USA). Patients were eligible if they were aged 18 years or more and were newly diagnosed with stage II to III locally advanced, resectable adenocarcinoma of the rectum with a distal tumour border of less than 12 cm from anal verge. Patients were ineligible if they had received anticancer therapy or surgery (except colostomy or ileostomy) 28 days or less before the first dose of study drug, previous pelvic radiotherapy, or previous treatment with poly (ADP-ribose) polymerase inhibitors. Enrolled patients received capecitabine (825 mg/m2 orally twice daily) with radiotherapy (50·4 Gy in 1·8 Gy fractions daily, approximately 5 days consecutively per week for about 5·5 weeks). Ve...Continue Reading

Citations

May 3, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E FokasUNKNOWN German Rectal Cancer Study Group
Dec 9, 2017·Diseases of the Colon and Rectum·Philippe Rouanet
Oct 13, 2018·The British Journal of Surgery·R CliffordD Vimalachandran
Feb 5, 2019·Molecular Oncology·Nicole M ReillyAlberto Bardelli
May 11, 2019·Future Oncology·Eleonora GhisoniGiorgio Valabrega
Mar 28, 2018·La Radiologia medica·Monica MangoniLorenzo Livi
Feb 27, 2019·Current Drug Targets·Yucui Zhao, Siyu Chen
Oct 19, 2019·Targeted Oncology·Esha SachdevMonica M Mita
Mar 21, 2020·Frontiers in Pharmacology·Stephen A JannettiThomas Reiner
Dec 14, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sabrina ArenaAlberto Bardelli
Dec 3, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rosemarie de HaanBaukelien van Triest
May 29, 2021·The Lancet Oncology·Robert Glynne-Jones, Stuart Glynne-Jones
Jul 27, 2021·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·David E KozonoEverett E Vokes
Aug 28, 2021·Biomedicines·Abdullah AlhusainiNiamh Lynam-Lennon
Aug 5, 2021·International Journal of Radiation Oncology, Biology, Physics·Leslie A ParselsMeredith A Morgan
Jun 9, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G MauriA Sartore-Bianchi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.